S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Molecular Templates (MTEM) Stock Forecast, Price & News

-0.11 (-9.82%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
355,084 shs
Average Volume
226,917 shs
Market Capitalization
$56.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

Molecular Templates logo

About Molecular Templates

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$38.70 million
Book Value
$0.84 per share


Net Income
$-83.01 million
Net Margins
Pretax Margin




Free Float
Market Cap
$56.90 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.61 out of 5 stars

Medical Sector

86th out of 1,416 stocks

Pharmaceutical Preparations Industry

33rd out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

Is Molecular Templates a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Molecular Templates stock.
View analyst ratings for Molecular Templates
or view top-rated stocks.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,410,000 shares, an increase of 24.8% from the April 15th total of 1,130,000 shares. Based on an average trading volume of 192,600 shares, the days-to-cover ratio is currently 7.3 days. Currently, 3.4% of the shares of the stock are sold short.
View Molecular Templates' Short Interest

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Molecular Templates

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) posted its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. The biotechnology company had revenue of $8.49 million for the quarter, compared to analyst estimates of $6.88 million. Molecular Templates had a negative net margin of 177.06% and a negative trailing twelve-month return on equity of 110.16%.
View Molecular Templates' earnings history

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates's stock reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

1 equities research analysts have issued 1 year target prices for Molecular Templates' stock. Their forecasts range from $4.50 to $9.00. On average, they expect Molecular Templates' stock price to reach $6.75 in the next year. This suggests a possible upside of 568.3% from the stock's current price.
View analysts' price targets for Molecular Templates
or view top-rated stocks among Wall Street analysts.

Who are Molecular Templates' key executives?
Molecular Templates' management team includes the following people:
  • Dr. Eric E. Poma Ph.D., CEO, Chief Scientific Officer & Director (Age 50, Pay $839.67k)
  • Ms. Jason S Kim, Pres & COO (Age 47, Pay $600.41k) (LinkedIn Profile)
  • Dr. Roger J. Waltzman M.B.A., M.D., Chief Medical Officer (Age 54, Pay $594.17k)
  • Mr. Sean McLennan, Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer (Age 51)
  • Ms. Megan C. Filoon, Gen. Counsel & Sec.
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 55)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 42)
  • Dr. Erin Willert Ph.D., Exec. VP of R&D (Age 40)
  • Dr. Jen-Sing Liu Ph.D., Exec. VP of Manufacturing (Age 59)
  • Dr. Nenad Sarapa M.D., M.S., Sr. VP of Clinical Devel.
What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different institutional and retail investors. Top institutional investors include Bellevue Group AG (19.67%), BlackRock Inc. (5.03%), Vanguard Group Inc. (4.63%), Frazier Life Sciences Management L.P. (2.44%), State Street Corp (1.14%) and Russell Investments Group Ltd. (0.81%). Company insiders that own Molecular Templates stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii and Target N V Biotech.
View institutional ownership trends for Molecular Templates

Which institutional investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Northern Trust Corp, Renaissance Technologies LLC, BlackRock Inc., Goldman Sachs Group Inc., UBS Group AG, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Molecular Templates
or view top insider-selling stocks.

Which institutional investors are buying Molecular Templates stock?

MTEM stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Bellevue Group AG, Russell Investments Group Ltd., Endurant Capital Management LP, State Street Corp, ClariVest Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., and Oppenheimer & Co. Inc..
View insider buying and selling activity for Molecular Templates
or or view top insider-buying stocks.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $1.01.

How much money does Molecular Templates make?

Molecular Templates has a market capitalization of $56.90 million and generates $38.70 million in revenue each year. The biotechnology company earns $-83.01 million in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Molecular Templates have?

Molecular Templates employs 261 workers across the globe.

When was Molecular Templates founded?

Molecular Templates was founded in 2009.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at (512) 869-1555, via email at [email protected], or via fax at 650-474-2529.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.